FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531803669> ?p ?o ?g. }

• W2531803669 abstract "Anti-malarial drug resistance continues to be a leading threat to malaria control efforts and calls for continued monitoring of waning efficacy of artemisinin-based combination therapy (ACT). Artesunate + sulfadoxine/pyrimethamine (AS + SP) is used for the treatment of uncomplicated Plasmodium falciparum malaria in India. However, resistance against AS + SP is emerged in northeastern states. Therefore, artemether-lumefantrine (AL) is the recommended first line treatment for falciparum malaria in north eastern states. This study investigates the therapeutic efficacy and safety of AL for the treatment of uncomplicated falciparum malaria in three malaria-endemic states in India. The data generated through this study will benefit the immediate implementation of second-line ACT as and when required.This was a one-arm prospective evaluation of clinical and parasitological responses for uncomplicated falciparum malaria using WHO protocol. Patients diagnosed with uncomplicated mono P. falciparum infection were administered six-dose regimen of AL over 3 days and subsequent follow-up was carried out up to 28 days. Molecular markers msp-1 and msp-2 were used to differentiate recrudescence and re-infection and K13 propeller gene was amplified and sequenced covering the codon 450-680.A total of 402 eligible patients were enrolled in the study from all four sites. Overall, adequate clinical and parasitological response (ACPR) was 98 % without PCR correction and 99 % with PCR correction. At three study sites, ACPR rates were 100 %, while at Bastar, cure rate was 92.5 % on day 28. No early treatment failure was found. The PCR-corrected endpoint finding confirmed that one late clinical failure (LCF) and two late parasitological failures (LPF) were recrudescences. The PCR corrected cure rate was 96.5 %. The mean fever clearance time was 27.2 h ± 8.2 (24-48 h) and the mean parasite clearance time was 30.1 h ± 11.0 (24-72 h). Additionally, no adverse event was recorded. Analysis of total 186 samples revealed a mutation in the k13 gene along with non-synonymous mutation at codon M579T in three (1.6 %) samples.AL is an efficacious drug for the treatment of uncomplicated falciparum malaria. However, regular monitoring of AL is required in view of malaria elimination initiatives, which will be largely dependent on therapeutic interventions, regular surveillance and targeted vector control." @default.
• W2531803669 created "2016-10-21" @default.
• W2531803669 creator A5006827008 @default.
• W2531803669 creator A5007761677 @default.
• W2531803669 creator A5009223223 @default.
• W2531803669 creator A5010627535 @default.
• W2531803669 creator A5011217153 @default.
• W2531803669 creator A5014556328 @default.
• W2531803669 creator A5020531421 @default.
• W2531803669 creator A5025093827 @default.
• W2531803669 creator A5034252637 @default.
• W2531803669 creator A5044798622 @default.
• W2531803669 creator A5046183202 @default.
• W2531803669 creator A5047094745 @default.
• W2531803669 creator A5047394224 @default.
• W2531803669 creator A5049427727 @default.
• W2531803669 creator A5051742104 @default.
• W2531803669 creator A5059057995 @default.
• W2531803669 creator A5064636636 @default.
• W2531803669 creator A5068017030 @default.
• W2531803669 creator A5080612680 @default.
• W2531803669 creator A5080722332 @default.
• W2531803669 creator A5083547831 @default.
• W2531803669 date "2016-10-13" @default.
• W2531803669 modified "2023-10-15" @default.
• W2531803669 title "Therapeutic efficacy of artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India" @default.
• W2531803669 cites W1189868779 @default.
• W2531803669 cites W1903447473 @default.
• W2531803669 cites W1970082198 @default.
• W2531803669 cites W1978173418 @default.
• W2531803669 cites W1993347313 @default.
• W2531803669 cites W2033864643 @default.
• W2531803669 cites W2066719680 @default.
• W2531803669 cites W2087154840 @default.
• W2531803669 cites W2104700616 @default.
• W2531803669 cites W2110243445 @default.
• W2531803669 cites W2114213072 @default.
• W2531803669 cites W2124634096 @default.
• W2531803669 cites W2145532326 @default.
• W2531803669 cites W2155740600 @default.
• W2531803669 cites W2156331763 @default.
• W2531803669 cites W2159536724 @default.
• W2531803669 cites W2161853348 @default.
• W2531803669 cites W2171199763 @default.
• W2531803669 cites W2178788332 @default.
• W2531803669 doi "https://doi.org/10.1186/s12936-016-1555-4" @default.
• W2531803669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5064902" @default.
• W2531803669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27737665" @default.
• W2531803669 hasPublicationYear "2016" @default.
• W2531803669 type Work @default.
• W2531803669 sameAs 2531803669 @default.
• W2531803669 citedByCount "17" @default.
• W2531803669 countsByYear W25318036692017 @default.
• W2531803669 countsByYear W25318036692018 @default.
• W2531803669 countsByYear W25318036692019 @default.
• W2531803669 countsByYear W25318036692020 @default.
• W2531803669 countsByYear W25318036692021 @default.
• W2531803669 countsByYear W25318036692022 @default.
• W2531803669 countsByYear W25318036692023 @default.
• W2531803669 crossrefType "journal-article" @default.
• W2531803669 hasAuthorship W2531803669A5006827008 @default.
• W2531803669 hasAuthorship W2531803669A5007761677 @default.
• W2531803669 hasAuthorship W2531803669A5009223223 @default.
• W2531803669 hasAuthorship W2531803669A5010627535 @default.
• W2531803669 hasAuthorship W2531803669A5011217153 @default.
• W2531803669 hasAuthorship W2531803669A5014556328 @default.
• W2531803669 hasAuthorship W2531803669A5020531421 @default.
• W2531803669 hasAuthorship W2531803669A5025093827 @default.
• W2531803669 hasAuthorship W2531803669A5034252637 @default.
• W2531803669 hasAuthorship W2531803669A5044798622 @default.
• W2531803669 hasAuthorship W2531803669A5046183202 @default.
• W2531803669 hasAuthorship W2531803669A5047094745 @default.
• W2531803669 hasAuthorship W2531803669A5047394224 @default.
• W2531803669 hasAuthorship W2531803669A5049427727 @default.
• W2531803669 hasAuthorship W2531803669A5051742104 @default.
• W2531803669 hasAuthorship W2531803669A5059057995 @default.
• W2531803669 hasAuthorship W2531803669A5064636636 @default.
• W2531803669 hasAuthorship W2531803669A5068017030 @default.
• W2531803669 hasAuthorship W2531803669A5080612680 @default.
• W2531803669 hasAuthorship W2531803669A5080722332 @default.
• W2531803669 hasAuthorship W2531803669A5083547831 @default.
• W2531803669 hasBestOaLocation W25318036691 @default.
• W2531803669 hasConcept C114851261 @default.
• W2531803669 hasConcept C126322002 @default.
• W2531803669 hasConcept C142724271 @default.
• W2531803669 hasConcept C159047783 @default.
• W2531803669 hasConcept C185032368 @default.
• W2531803669 hasConcept C203014093 @default.
• W2531803669 hasConcept C2776120307 @default.
• W2531803669 hasConcept C2777035104 @default.
• W2531803669 hasConcept C2778048844 @default.
• W2531803669 hasConcept C2778059366 @default.
• W2531803669 hasConcept C2778118209 @default.
• W2531803669 hasConcept C2778301690 @default.
• W2531803669 hasConcept C2778371730 @default.
• W2531803669 hasConcept C2778629330 @default.
• W2531803669 hasConcept C2780441369 @default.
• W2531803669 hasConcept C2780780316 @default.
• W2531803669 hasConcept C2781413609 @default.
• W2531803669 hasConcept C71924100 @default.

• next